Bioprojet
Quick facts
Phase 3 pipeline
- BF2.649 · Neurology
BF2.649 is a histamine H3 receptor antagonist that increases histamine signaling in the brain to promote wakefulness and cognitive function. - BF2.649 add on Modafinil · Neurology / Sleep Medicine
BF2.649 is a histamine H3 receptor antagonist that enhances wakefulness and cognitive function when combined with modafinil's dopamine/norepinephrine reuptake inhibition. - BF2.649 (pitolisant) · Neurology
Pitolisant is a selective histamine H3 receptor antagonist that increases histamine release in the brain to promote wakefulness.
Phase 2 pipeline
- BP1.3656 high dose
- BP1.3656 intermediate dose · Cardiovascular
BP1.3656 intermediate dose is a medication that helps to lower blood pressure by affecting the body's ability to regulate blood vessel constriction. - BP1.3656 low dose · Cardiovascular
BP1.3656 low dose is a medication that lowers blood pressure by acting on the renin-angiotensin system. - BP1.4979
- BP1.4979 active drug · Cardiovascular
BP1.4979 is a small molecule drug that targets the renin-angiotensin system.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: